Magic Mushrooms Help Smokers Quit 6x Better Than Patches

A single dose of magic mushrooms might be the smoking cessation breakthrough we've been waiting for.

Researchers at Johns Hopkins University just published results from a clinical trial that surprised everyone involved. Smokers who took one dose of psilocybin, the active compound in magic mushrooms, were six times more likely to stay cigarette-free than those using nicotine patches.

"I was surprised by the sheer magnitude of the effect," said lead author Matthew Johnson, a psychiatry professor at Johns Hopkins.

The study enrolled 82 current smokers and split them into two groups. Everyone received 13 weeks of cognitive behavioral therapy for quitting. One group used nicotine patches while the other took a high dose of pure psilocybin during a single guided session.

The psilocybin experience looked like this: participants lay in a comfortable room wearing eye shades and listening to soft music, with trained facilitators nearby for support. The session was self-directed, letting each person navigate their own experience.

Six months later, 17 people in the psilocybin group had stayed off cigarettes. Only four people in the patch group succeeded.

Why This Inspires

This approach works completely differently than any existing quit-smoking medication. The seven approved medications in the US all target nicotine receptors directly, essentially replacing or mimicking the substance people are trying to quit.

Psilocybin takes a different route entirely. "When people are on a compound like psilocybin, the brain is communicating with itself in very different ways," Johnson explained.

What follows seems to be a genuine shift in perspective and a new sense of agency. Participants reported being able to step outside their usual patterns and try something different.

Dr. Brian Barnett, an addiction psychiatrist not involved in the study, suspects the intensive therapeutic structure around the session was just as important as the drug itself. "It's really harnessing the neuroplastic and learning effects that happen after the exposure," he said.

The timing couldn't be better. Smoking remains the leading cause of preventable death in the United States. Even with the best available medications and counseling combined, 70 percent of people return to smoking after trying to quit.

"It's been 20 years since we've had a new medication to help people quit smoking," said Megan Piper, director of the UW Center for Tobacco Research and Intervention. "We need something novel, and this is definitely a novel approach."

The National Institutes of Health has already funded Johnson for a larger trial that includes a placebo arm and more diverse participants. Brain imaging data from the current study is still being analyzed and may reveal more about how psilocybin creates these dramatic results.

After two decades of waiting, a breakthrough in smoking cessation might finally be on the horizon.